Novo Nordisk CEO Mike Doustdar says the obesity drug market will not be a winner-take-all battle with rival Eli Lilly, emphasizing differentiation among treatments like pills and injectables.
Doustdar argues investors underestimate demand for choice, citing multiple insulin brands as a model for future GLP-1 obesity drugs with varying benefits.
The Wegovy pill currently holds about 90% of the oral GLP-1 market, giving Novo an edge over Lilly's Foundayo pill despite Lilly's strength in injectables like Zepbound.
Analysts project the obesity drug market could exceed $100 billion by 2030, supporting Doustdar's view of room for multiple players amid intense competition.
Sources:
Novo CEO says obesity market won't be winner-take-all ...
Obesity not a winner-takes-all game, Novo CEO says
Novo Nordisk CEO Mike Doustdar said investors are ...
Health News | Today's Latest Stories
Novo Nordisk CEO Doustdar says obesity drugs market won't be dominated by one player
Novo Says Priority Is Obesity Despite Investor Calls to Expand
Novo CEO says obesity market won't be winner-take-all ...
As Lilly rivalry flares, Novo CEO sets out Wegovy launch strategy By Reuters
Novo Nordisk faces defining year in the obesity drug market - CNBC
Novo hoped its next obesity drug would close the gap. ...
Novo Nordisk's CagriSema trial deals blow in obesity drug ...
Eli Lilly gaining in GLP-1 market over Novo Nordisk, earnings show